{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-275889","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.441315+00:00","generated_at":"2026-05-16T21:22:20.066543+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TScan Q3 net loss $35.7M; pauses solid tumor enrollment, advances heme pivotal trial","bullets":["Revenue $2.5M (up from $1.0M YoY); net loss $35.7M vs $29.9M; cash $184.5M funds into H2 2027.","FDA agreed on pivotal trial design for TSC-101 in AML/MDS; pivotal launch expected Q2 2026.","Strategic decision: prioritize heme program, pause PLEXI-T solid tumor enrollment; shift to in vivo engineering.","Plans to present updated ALLOHA heme data at ASH Dec 2025; two IND submissions for heme candidates in Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-275889","json":"https://secwatch.observer/filing/0001193125-25-275889.json","markdown":"https://secwatch.observer/filing/0001193125-25-275889.md","text":"https://secwatch.observer/filing/0001193125-25-275889.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312525275889/0001193125-25-275889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312525275889/tcrx-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:22:20.066543+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}